Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

On Friday, Amgen Inc (AMGN) stock saw a decline, ending the day at $283.61 which represents a decrease of $-12.32 or -4.16% from the prior close of $295.93. The stock opened at $291.5 and touched a ...

On November 13, 2024, Amgen filed a BPCIA complaint in the District Court for the Eastern District of North Carolina against Accord Biopharma, Inc.; Accord Healthcare, Inc.; and Intas Pharmaceuticals, ...